Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase

Anaplastic lymphoma kinase (ALK) is validated as a therapeutic molecular target in multiple malignancies, such as non-small cell lung cancer (NSCLC). However, the feasibility of targeted therapies exerted by ALK inhibitors is inevitably hindered owing to drug resistance. The emergence of clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Shuai, Wang, Qing, Qi, Xuesen, Liu, Yudi, Li, Guozhen, Lu, Shaoyong, Mou, Linkai, Chen, Xiangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733690/
https://www.ncbi.nlm.nih.gov/pubmed/35004700
http://dx.doi.org/10.3389/fcell.2021.808864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733690/
https://www.ncbi.nlm.nih.gov/pubmed/35004700
http://dx.doi.org/10.3389/fcell.2021.808864

Ejemplares similares